Fagron N.V. | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
21,618.00
46,299.00
16,108.00
6,364.00
55,965.00
54,835
Other Funds
75,067.00
34,958.00
56,615.00
34,638.00
9,650.00
7,799
Funds from Operations
53,449.00
81,257.00
40,507.00
28,274.00
65,615.00
62,634
Changes in Working Capital
9,774.00
4,229.00
1,820.00
2,969.00
9,927.00
7,727
Net Operating Cash Flow
43,675.00
77,028.00
42,327.00
31,243.00
55,688.00
54,907
Capital Expenditures
15,822.00
20,656.00
22,052.00
14,777.00
10,032.00
Sale of Fixed Assets & Businesses
53,606.00
23,042.00
72,450.00
-
-
Purchase/Sale of Investments
101,317.00
196,171.00
96,674.00
8,155.00
1,709.00
Net Investing Cash Flow
63,533.00
193,785.00
46,276.00
22,932.00
11,741.00
Cash Dividends Paid - Total
18,766.00
22,199.00
31,366.00
-
-
Issuance/Reduction of Debt, Net
122,152.00
109,785.00
628.00
8,392.00
275,832.00
Net Financing Cash Flow
85,928.00
89,658.00
30,476.00
207,699.00
275,832.00
Net Change in Cash
63,060.00
26,860.00
33,076.00
220,110.00
234,814.00
Free Cash Flow
27,853.00
56,372.00
20,275.00
16,466.00
45,656.00
Change in Capital Stock
17,458.00
2,072.00
1,518.00
216,092.00
-
Exchange Rate Effect
3,010.00
239.00
1,349.00
4,100.00
2,929.00

About Fagron

View Profile
Address
Venecoweg 20A
Nazareth VL 9810
Belgium
Employees -
Website http://www.fagron.com
Updated 07/08/2019
Fagron NV engages in the provision of development, marketing, and distribution of healthcare products and services. It operates through the following segments: Fagron Specialty Pharma Services (FSPS); Fagron Trademarks (FTM); Fagron Essentials (FE); and HL Technology. The FSPS segment refers to all personalized medication that is prepared in sterile and non-sterile compounding facilities in Europe, the United States, Colombia and South Africa.